Article
The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.
Respiration; international review of thoracic diseases - 1 Jan 2011
Wojas-Krawczyk Kamila, Krawczyk Paweł, Mlak Radosław, Kucharczyk Tomasz, Kowalski Dariusz M, Krzakowski Maciej, Milanowski Janusz
Abstract excerpt
BACKGROUND: Tyrosine kinase inhibitors of EGFR (TKI-EGFR) induced response in only 10% of Caucasian non-small-cell lung cancer patients in second- or third-line treatment. Independent predictive factors for qualification to TKI-EGFR treatment have not been assessed. In 2008, a prognostic index was reported for patients treated with erlotinib in the BR.21 trial, but its application for real, unselected patients is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
